Compare CCS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | VIR |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2014 | 2019 |
| Metric | CCS | VIR |
|---|---|---|
| Price | $51.68 | $9.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $64.80 | $19.43 |
| AVG Volume (30 Days) | 253.8K | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $4,117,816,000.00 | $68,556,000.00 |
| Revenue This Year | N/A | $270.22 |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | $61.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.42 | $4.16 |
| 52 Week High | $76.00 | $11.66 |
| Indicator | CCS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 43.91 |
| Support Level | $51.57 | $8.47 |
| Resistance Level | $66.29 | $10.29 |
| Average True Range (ATR) | 1.87 | 0.41 |
| MACD | -0.39 | -0.15 |
| Stochastic Oscillator | 7.12 | 12.85 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.